Medindia

X

Reportlinker Adds UCB S.A.: PharmaVitae Profile

Wednesday, February 17, 2010 Corporate News J E 4
Advertisement


NEW YORK, Feb. 16 Reportlinker.com announces that a new market research report is available in its catalogue:

UCB S.A.: PharmaVitae Profile

http://www.reportlinker.com/p0177525/UCB-SA-PharmaVitae-Profile.html

Introduction

This analysis examines the historical and forecast performance for UCB in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Reasons to Purchase

*Benchmark UCB's performance against key rivals in the prescription pharmaceutical sector

*Determine the extent to which UCB's next-generation of CNS medications will protect revenues from the decline of its Keppra franchise

*Examine the long-term sales potential offered by Cimzia after its long-awaited approvals for Crohn's disease and rheumatoid arthritis

ABOUT DATAMONITOR HEALTHCARE 2

About the PharmaVitae team 2

Chapter 1 About this profile 3

PharmaVitae Explorer database 3

Chapter structure 3

Executive summary 3

Quarterly news update 3

Company introduction 3

Company sales 4

Company financials 4

Key products and competitors 4

Data sourcing 4

Sales data 4

Analyst consensus 4

Chapter 2 Executive summary 5

Key findings 5

Prescription pharmaceutical sales and growth rate performance, 2002-14 6

Financial performance, 2002-14 7

UCB: PharmaVitae forecasts at a glance 8

Strategic insight 9

Epilepsy launches central to overcoming Keppra generics 9

Vimpat and Rikelta in line to replace Keppra as UCB's next-generation AED medications 9

Biopharmaceutical business model yet to deliver growth 11

SWOT analysis 12

Table of Contents 13

Table of figures 15

Chapter 3 Quarterly news update 16

Product developments 16

Deals and alliances 18

Product deals 18

Company announcements 19

Chapter 4 Company introduction 20

Key findings 20

Background 21

Key corporate developments 21

M&A history 22

Celltech 22

Schwarz Pharma 23

Chapter 5 Company sales 24

Key findings 24

Prescription pharmaceutical sales and growth rate analysis, 2002-14 25

Product analysis 26

Product analysis, 2002-08 27

Product analysis, 2008-14 30

Therapy area analysis 33

Geographic analysis 35

Launch/core/expiry analysis 37

Explanation of launch/core/expiry analysis 37

Launch analysis, 2008-14 38

Core analysis, 2008-14 39

Expiry analysis, 2008-14 40

Generics analysis, 2008-14 41

Launch/core/expiry configuration, 2008-14 42

Molecule type analysis 43

Externalization analysis 45

Chapter 6 Company financials 47

Key findings 47

Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2002-08 48

Operating costs and profit analysis 49

Operating costs and profit analysis, 2002-08 50

Operating cost ratio and profit margin analysis, 2002-08 51

Operating cost ratio and profit margin analysis, 2008-14 52

Operating costs and profit analysis, 2008-14 53

Chapter 7 Key products and competitors 54

Key findings 54

Overview 55

Central nervous system 56

Keppra/Keppra XR 56

Overview 57

Sales forecast 58

Gold standard anti-epileptic drug 58

Launch of Keppra XR in September 2008 represents a clear lifecycle management strategy 59

Generics will erode a significant portion of the Keppra franchise's market share 60

Japan market penetration offers franchise some growth opportunity 60

Rikelta 61

Overview 62

Sales forecast 63

Next-generation version of Keppra currently in phase III trials 63

Datamonitor expects brivaracetam's target population to be treatment-refractory epilepsy patients 64

Neupro 65

Overview 66

Sales forecast 67

Novel Parkinson's formulation 67

Product recall in the US expected to slow uptake 67

Improved compliance and symptom control set to drive uptake 68

Vimpat 70

Overview 71

Sales forecast 72

Vimpat is the newest member of UCB's antiepileptic franchise 72

Approval as an adjunctive epilepsy treatment set to boost UCB offering 73

Neuropathic pain use rejected by FDA 73

Cannibalization of sales by brivaracetam represents a key threat to Vimpat 74

Immunology & inflammation 75

Cimzia 75

Overview 76

Sales forecast 77

UCB's novel anti-TNF mAb finally gets green light 77

Non-responder patient population and pricing offer key route to uptake 78

Cimzia is back in Phase III for Crohn's disease in the EU - Datamonitor updated its forecast to reflect impact of a Cimzia launch 78

Chapter 8 Appendix 80

R&D pipeline 80

References 81

Abbreviations 81

Exchange rates 83

About Datamonitor 84

About Datamonitor Healthcare 84

Datamonitor consulting 84

Disclaimer 86

List of Tables

Table 1: UCB - PharmaVitae forecasts at a glance 8

Table 2: UCB key product developments, 2009 16

Table 3: UCB deals and alliances, 2009 18

Table 4: UCB company announcements, 2009 19

Table 5: UCB product portfolio overview ($m), 2002-08 27

Table 6: UCB product portfolio overview ($m), 2008-14 30

Table 7: UCB prescription pharmaceutical sales by therapy area ($m), 2008-14 34

Table 8: UCB prescription pharmaceutical sales by geographic region ($m), 2008-14 36

Table 9: UCB launch portfolio overview ($m), 2008-14 38

Table 10: UCB core portfolio overview ($m), 2008-14 39

Table 11: UCB expiry portfolio overview ($m), 2008-14 40

Table 12: UCB generics portfolio overview ($m), 2008-14 41

Table 13: UCB prescription pharmaceutical sales by molecule type ($m), 2008-14 44

Table 14: UCB prescription pharmaceutical sales by source ($m), 2008-14 46

Table 15: Total UCB sales by business unit ($m), 2002-08 48

Table 16: UCB operating revenue/cost analysis ($m), 2002-08 50

Table 17: UCB operating cost ratio analysis (% of total revenues), 2002-08 51

Table 18: UCB operating cost ratio analysis (% of total revenues), 2008-14 52

Table 19: UCB operating revenue/cost analysis ($m), 2008-14 53

Table 20: Key products overview 55

Table 21: Keppra/Keppra XR: overview 57

Table 22: Keppra/Keppra XR: sales forecast ($m), 2008-14 58

Table 23: Rikelta: overview 62

Table 24: Rikelta: sales forecast ($m), 2008-14 63

Table 25: Neupro: overview 66

Table 26: Neupro: sales forecast ($m), 2008-14 67

Table 27: Vimpat: overview 71

Table 28: Vimpat: sales forecast ($m), 2008-14 72

Table 29: Cimzia: overview 76

Table 30: Cimzia: sales forecast ($m), 2008-14 77

Table 31: UCB's R&D pipeline (Phase I-registration) 80

Table 32: Exchange rates, 2009 83

List of Figures

Figure 1: The PharmaVitae Explorer 3

Figure 2: UCB prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14 6

Figure 3: UCB's financial performance ($m), 2002-14 7

Figure 4: UCB's epilepsy portfolio, sales ($m), 2002-14 10

Figure 5: UCB SWOT analysis 12

Figure 6: UCB prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14 25

Figure 7: Key product sales ($m), 2002-14 26

Figure 8: UCB key sales growth drivers and resistors ($m), 2002-08 29

Figure 9: UCB key sales growth drivers and resistors ($m), 2008-14 32

Figure 10: UCB prescription pharmaceutical sales by therapy area ($m), 2002-14 33

Figure 11: UCB prescription pharmaceutical sales by geographic region ($m), 2002-14 35

Figure 12: UCB launch/core/expiry configuration ($m), 2008-14 42

Figure 13: UCB prescription pharmaceutical sales by molecule type ($m), 2002-14 43

Figure 14: UCB prescription pharmaceutical sales by source ($m), 2002-14 45

Figure 15: UCB operating revenue/cost analysis ($m), 2002-14 49

To order this report:

Pharmaceutical Industry: UCB S.A.: PharmaVitae Profile

More Market Research Report

Check our Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg Reportlinker Email: nbo@reportlinker.com US: (805)652-2626 Intl: +1 805-652-2626

SOURCE Reportlinker
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
CVS Caremark Study Finds Value Based Insurance Des...
S
"The Other Aspect of Health Care: DENTAL CARE"